Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김형래 | * |
dc.date.accessioned | 2019-08-22T16:30:03Z | - |
dc.date.available | 2019-08-22T16:30:03Z | - |
dc.date.issued | 2019 | * |
dc.identifier.issn | 1042-8194 | * |
dc.identifier.issn | 1029-2403 | * |
dc.identifier.other | OAK-25248 | * |
dc.identifier.uri | https://dspace.ewha.ac.kr/handle/2015.oak/251215 | - |
dc.description.abstract | Allogeneic hematopoietic stem cell transplantation (allo-HSCT) has been the only treatment option for acute myeloid leukemia (AML) refractory to induction chemotherapy, with only 10-20% of patients achieving long-term survival. Certain donor genotypes may confer leukemia-clearing effects after allo-HSCT. We performed whole-exome sequencing of five pairs of the germ lines in AML patients who achieved long-term remission after allo-HSCT and in their donors, and found two significant variants: EGFR c.2982C>T and CDH11 c.945G>A. To validate the protective effects of these leukemia-clearing genotypes (LCGs), AML patients who received allo-HSCT in a complete-remission status were also analyzed. Twenty-two of 96 donors (22.9%) had LCGs in their genomes, and overall survival was significantly longer in patients who received allo-HSCT from donors with germ-line LCGs (hazard ratio=0.47, 95% confidence interval=0.24-0.94, p=.033). These findings indicate that donor germ-line LCGs have phenotypically leukemia-clearing effects and are biomarkers for predicting clinical outcomes in allogeneic transplantation in AML patients. | * |
dc.language | English | * |
dc.publisher | TAYLOR & | * |
dc.publisher | FRANCIS LTD | * |
dc.subject | Donor genotype | * |
dc.subject | hematopoietic stem cell transplantation | * |
dc.subject | acute myeloid leukemia | * |
dc.subject | whole-exome sequencing | * |
dc.subject | survival | * |
dc.title | Discovery of donor genotype associated with long-term survival of patients with hematopoietic stem cell transplantation in refractory acute myeloid leukemia | * |
dc.type | Article | * |
dc.relation.issue | 7 | * |
dc.relation.volume | 60 | * |
dc.relation.index | SCIE | * |
dc.relation.index | SCOPUS | * |
dc.relation.startpage | 1775 | * |
dc.relation.lastpage | 1781 | * |
dc.relation.journaltitle | LEUKEMIA & LYMPHOMA | * |
dc.identifier.doi | 10.1080/10428194.2018.1542142 | * |
dc.identifier.wosid | WOS:000478841300022 | * |
dc.author.google | Ock, Chan-Young | * |
dc.author.google | Seo, Heewon | * |
dc.author.google | Kim, Dae-Yoon | * |
dc.author.google | Min, Byung Joo | * |
dc.author.google | Park, Yoomi | * |
dc.author.google | Cheong, Hyun Sub | * |
dc.author.google | Kim, Hyung-Lae | * |
dc.author.google | Song, Eun-Young | * |
dc.author.google | Kim, Inho | * |
dc.author.google | Yoon, Sung-Soo | * |
dc.author.google | Kim, Ju Han | * |
dc.author.google | Koh, Youngil | * |
dc.contributor.scopusid | 김형래(57202558385;57219111690;57567109600) | * |
dc.date.modifydate | 20240118123830 | * |